Samsung Biologics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	1,878,044	1,784,352	1,083,316	857,691	798,056	393,589
Depreciation & Amortization	564,795	633,637	599,101	489,782	308,264	161,789
Loss (Gain) From Sale of Assets	5,019	5,454	2,199	3,866	2,588	7,466
Asset Writedown & Restructuring Costs	3,096	10,697	62,655	-	-	725.89
Loss (Gain) From Sale of Investments	-759.34	-759.34	-597.28	-5,152	-72,653	-269.12
Loss (Gain) on Equity Investments	-22,048	-43,071	-2,660	499.42	-27,260	-13,853
Provision & Write-off of Bad Debts	-6,289	-811.8	-6,380	21,511	22,407	4,857
Other Operating Activities	25,949	-10,197	-33,004	-711.89	185,130	135,132
Change in Accounts Receivable	148,781	292,751	-450,992	30,127	-305,336	-120,660
Change in Inventory	-401,159	-388,182	-236,200	-273,896	-179,912	-370,571
Change in Accounts Payable	217,184	-226,269	409,295	267,037	134,594	21,060
Change in Unearned Revenue	-123,664	37,157	10.58	27,199	44,017	-
Change in Other Net Operating Assets	43,562	153,049	232,511	248,276	43,151	235,330
Operating Cash Flow	2,332,509	2,247,807	1,659,255	1,666,229	953,048	454,596
Operating Cash Flow Growth	13.65%	35.47%	-0.42%	74.83%	109.65%	124.95%
Capital Expenditures	-852,774	-1,391,741	-1,303,573	-995,071	-956,840	-406,254
Sale of Property, Plant & Equipment	1,012	1,637	1,389	2,811	64.01	37.64
Cash Acquisitions	-515,592	-	-601,956	-1,071,525	-1,081,821	-
Sale (Purchase) of Intangibles	-64,213	-83,333	-73,952	-110,254	-52,386	-14,898
Investment in Securities	-580,942	-388,989	734,318	607,760	-1,015,673	-512,375
Other Investing Activities	-0	-0	-0	-0	178.52	-0
Investing Cash Flow	-2,012,509	-1,862,426	-1,243,776	-1,566,305	-3,106,477	-933,489
Short-Term Debt Issued	-	40,000	237,000	758,500	593,750	50,000
Long-Term Debt Issued	-	45,000	892,659	45,000	211,903	648,356
Total Debt Issued	40,000	85,000	1,129,659	803,500	805,653	698,356
Short-Term Debt Repaid	-	-130,000	-684,500	-686,783	-496,988	-30,000
Long-Term Debt Repaid	-	-267,075	-878,947	-751,967	-496,906	-171,734
Total Debt Repaid	-284,488	-397,075	-1,563,447	-1,438,750	-993,894	-201,734
Net Debt Issued (Repaid)	-244,488	-312,075	-433,788	-635,250	-188,241	496,622
Issuance of Common Stock	-	-	-	-	3,200,751	-
Repurchase of Common Stock	-92,013	-92,013	-	-	-	-
Other Financing Activities	-216,417	-216,417	-	200	-12,430	-0
Financing Cash Flow	-552,918	-620,504	-433,788	-635,050	3,000,080	496,622
Foreign Exchange Rate Adjustments	1,221	-7,247	41,593	12,245	-3,242	831.1
Net Cash Flow	-231,697	-242,370	23,284	-522,882	843,409	18,560
Free Cash Flow	1,479,735	856,067	355,682	671,158	-3,792	48,343
Free Cash Flow Growth	628.50%	140.68%	-47.01%	-	-	-22.56%
Free Cash Flow Margin	30.73%	18.79%	10.17%	18.17%	-0.13%	3.08%
Free Cash Flow Per Share	24347.74	12775.13	4997.47	14498.68	-83.52	1123.38
Cash Interest Paid	33,735	37,081	62,086	63,486	33,940	18,594
Cash Income Tax Paid	596,869	602,362	307,026	319,321	188,473	42,369
Levered Free Cash Flow	1,116,874	515,493	66,655	-446,653	21,978	62,860
Unlevered Free Cash Flow	1,134,951	533,725	87,982	-395,655	62,019	72,052
Change in Working Capital	-115,297	-131,493	-45,375	298,743	-263,485	-234,840